Cleared Traditional

K934390 - OSCILLATING BONE SAW BLADE, 6200 SERIES (FDA 510(k) Clearance)

Class I General & Plastic Surgery device.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 1994
Decision
139d
Days
Class 1
Risk

K934390 is an FDA 510(k) clearance for the OSCILLATING BONE SAW BLADE, 6200 SERIES. Classified as Blade, Saw, General & Plastic Surgery, Surgical (product code GFA), Class I - General Controls.

Submitted by Boehringer Laboratories (Norristown, US). The FDA issued a Cleared decision on January 26, 1994 after a review of 139 days - within the typical 510(k) review window.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4820 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General & Plastic Surgery review framework, consistent with the majority of Class II 510(k) submissions.

View all Boehringer Laboratories devices

Submission Details

510(k) Number K934390 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 09, 1993
Decision Date January 26, 1994
Days to Decision 139 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
25d slower than avg
Panel avg: 114d · This submission: 139d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code GFA Blade, Saw, General & Plastic Surgery, Surgical
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4820
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.